Puma Biotechnology, Inc.
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$38.7M
Doctors Paid
9,190
Transactions
37,663
2024 Total
$3.5M
Payment Breakdown by Category
Research$31.0M (80.1%)
Consulting$3.6M (9.3%)
Food & Beverage$801,763 (2.1%)
Travel$610,940 (1.6%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $31.0M | 1,887 | 80.1% |
| Consulting Fee | $3.6M | 969 | 9.3% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $2.3M | 818 | 6.0% |
| Food and Beverage | $801,763 | 31,188 | 2.1% |
| Travel and Lodging | $610,940 | 2,465 | 1.6% |
| Space rental or facility fees (teaching hospital only) | $314,339 | 132 | 0.8% |
| Grant | $10,000 | 1 | 0.0% |
| Compensation for serving as faculty or as a speaker for an accredited or certified continuing education program | $5,897 | 7 | 0.0% |
| Education | $2,102 | 196 | 0.0% |
Payments by Type
Research
$31.0M
1,887 transactions
General
$7.7M
35,776 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| AN OPEN-LABEL, PHASE 2 STUDY OF NERATINIB IN PATIENTS WITH SOLID TUMORS WITH SOMATIC HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR, HER2, HER3) MUTATIONS OR EGFR GENE AMPLIFICATION | $4.6M | 0 | 300 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF NERATINIB (HKI-272) AFTER TRASTUZUMAB IN WOMEN WITH EARLY-STAGE HER-2/NEU OVEREXPRESSED/AMPLIFIED BREAST CANCER | $1.7M | 3 | 112 |
| AN OPEN-LABEL, PHASE 2 BASKET STUDY OF NERATINIB IN PATIENTS WITH SOLID TUMORS WITH SOMATIC ACTIVATING HER MUTATIONS | $1.7M | 0 | 72 |
| An Open-label, Phase 2 Study of Neratinib in Patients With Solid Tumors | $1.7M | 0 | 115 |
| An Open-label, Phase 2 Study of Neratinib in Patients With Solid Tumors With Somatic Human Epidermal | $1.6M | 0 | 86 |
| An Open-Label Study to Characterize the Incidence and Severity of Diarrhea in Patients with Early | $1.6M | 0 | 54 |
| . | $1.4M | 0 | 11 |
| THIS IS AN OPEN-LABEL, NON-RANDOMIZED, MULTICENTER, MULTINATIONAL, PHASE 2 STUDY | $1.2M | 0 | 119 |
| A STUDY OF ALISERTIB IN PATIENTS WITH EXTENSIVE STAGE SMALL CELL LUNG CANCER (ALISCA-LUNG1) | $1.1M | 0 | 177 |
| An Open?Label Study to Characterize the Incidence and Severity of Diarrhea | $1.0M | 0 | 105 |
| BASKET STUDY OF NERATINIB IN PARTICIPANTS WITH SOLID TUMORS HARBORING SOMATIC HER2 OR EGFR EXON 18 MUTATIONS (SUMMIT) | $911,655 | 0 | 9 |
| A Phase II Study Evaluating the Combination of Neratinib Plus Trastuzumab or Neratinib Plus Cetuximab in Patients with "Quadruple Wild-Type" (KRAS/NRAS/BRAF/PIK3CA Wild-Type) Metastatic Colorectal Cancer Based on HER2 Status: Amplified, Non-Amplified (Wild-Type) or Mutated | $805,972 | 0 | 1 |
| AN OPEN LABEL, PHASE 2 STUDY OF NERATINIB IN PATIENTS WITH SOLID TUMORS WITH SOMATIC HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR, HER2, HER3) MUTATIONS OR EGFR GENE AMPLIFICATION | $756,293 | 0 | 43 |
| AN OPEN-LABEL STUDY TO CHARACTERIZE THE INCIDENCE AND SEVERITY OF DIARRHEA | $712,730 | 0 | 34 |
| AN OPEN-LABEL STUDY TO CHARACTERIZE THE INCIDENCE AND SEVERITY OF DIARRHEA IN PATIENTS WITH EARLY-STAGE HER2+ BREAST CANCER TREATED WITH NERATINIB AND INTENSIVE LOPERAMIDE PROPHYLAXIS | $630,803 | 0 | 39 |
| A STUDY OF NERATINIB PLUS CAPECITABINE VERSUS LAPATINIB PLUS CAPECITABINE IN PATIENTS WITH HER2+ | $523,614 | 0 | 36 |
| A Phase Ib/II Dose-Escalation Study Evaluating the Combination of Trastuzumab Emtansine (T-DM1) with Neratinib in Women with Metastatic HER2-Positive Breast Cancer | $476,857 | 0 | 1 |
| A Phase II Study of Neratinib alone and in Combination with Fulvestrant in Metastatic HER2 Non-amplified but HER2 Mutant Breast Cancer | $363,238 | 0 | 2 |
| PHASE I STUDY OF THE PAN-ERBB INHIBITOR NERATINIB GIVEN IN COMBINATION WITH EVEROLIMUS, PALBOCICLIB, OR TRAMETINIB IN ADVANCED CANCER SUBJECTS WITH EGFR MUTATION/AMPLIFICATION, HER2 MUTATION/AMPLIFICATION, OR HER3/4 MUTATION OR KRAS MUTATION | $349,363 | 0 | 2 |
| AN OPEN LABEL, PHASE II TRIAL OF PRE-OPERATIVE NERATINIB AND ENDOCRINE THERAPY WITH TRASTUZUMAB IN TRIPLE POSITIVE BREAST CANCERS HCRN-BRE17-141 | $325,650 | 0 | 7 |
| A Study of Neratinib Plus Capecitabine versus Lapatinib Plus Capecitabine(NALA) | $301,426 | 0 | 56 |
| ALISERTIB WITH OR WITHOUT FULVESTRANT IN TREATING PATIENTS WITH LOCALLY ADVANCED OR METASTATIC ENDOCRINE RESISTANT BREAST CANCER | $299,864 | 0 | 1 |
| A Randomized, Double-Blind, Placebo-Controlled Trial Of Neratinib | $298,949 | 1 | 124 |
| A PHASE 2 STUDY OF NERATINIB WITH OR WITHOUT FULVESTRANT IN HER2-POSITIVE, ER-POSITIVE METASTATIC BREAST CANCER | $293,466 | 0 | 3 |
| A Study of Neratinib Plus Capecitabine versus Lapatinib Plus Capecitabine in Patients with HER2+ | $286,452 | 0 | 115 |
| IMPACT Profiling in Patients with Advanced Cervix Cancer | $275,250 | 0 | 7 |
| A PHASE II TRIAL OF HKI-272 (NERATINIB), NERATINIB AND CAPECITABINE, AND ADO-TRASTUZUMAB EMTANSINE FOR PATIENTS WITH HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2)-POSITIVE BREAST CANCER AND BRAIN METASTASES | $256,160 | 0 | 2 |
| A PHASE II STUDY OF ALISERTIB, AN INVESTIGATIONAL DRUG, IN PATIENTS WITH EXTENSIVE-STAGE SMALL CELL LUNG CANCER (ES-SCLC) | $253,935 | 0 | 13 |
| A STUDY OF ALISERTIB IN COMBINATION WITH ENDOCRINE THERAPY IN PATIENTS WITH HR-POSITIVE, HER2-NEGATIVE RECURRENT OR METASTATIC BREAST CANCER (ALISCA-BREAST1) | $253,397 | 0 | 14 |
| Evaluating Neratinib in orthotopic PDX models of breast cancer brain metastases | $232,418 | 0 | 1 |
Payments by Medical Specialty
Top Paid Doctors
| Doctor | Specialty | Location | Total | 2024 |
|---|---|---|---|---|
| Adrian Senderowicz, Md, MD | Medical Oncology | Bethesda, MD | $1.4M | $0 |
| Jan Van Tornout, Md, MD | Pediatric Hematology-Oncology | Los Angeles, CA | $469,200 | $0 |
| Anne O'dea, M.d, M.D | Medical Oncology | Westwood, KS | $410,152 | $0 |
| Michel Velez, Md, MD | Internal Medicine | Orlando, FL | $299,081 | $0 |
| Dr. Suresh Ratnam, Md, MD | Medical Oncology | Mcallen, TX | $246,813 | $0 |
| Francis Arena, Md, MD | Internal Medicine | Lake Success, NY | $199,654 | $0 |
| Mr. Ruemu Birhiray, Md, MD | Hematology & Oncology | Indianapolis, IN | $183,395 | $0 |
| Dr. Brian Leyland-Jones, M.d, M.D | Hematology & Oncology | Sioux Falls, SD | $181,521 | $0 |
| Maria Theodoulou, Md, MD | Medical Oncology | Albany, NY | $176,359 | $0 |
| Dr. Vijayakrishna Gadi, M.d. Phd, M.D. PHD | Hematology & Oncology | Seattle, WA | $146,597 | $0 |
| Dr. Steven Sorscher, Md, MD | Medical Oncology | Winston Salem, NC | $130,000 | $0 |
| Dr. Danielle Sterrenberg, M.d, M.D | Hematology & Oncology | Los Angeles, CA | $110,121 | $0 |
| Dr. Melissa Brammer, M.d., M.p.h, M.D., M.P.H | Medical Oncology | South San Francisco, CA | $106,241 | $0 |
| Dr. Adam Brufsky, Md, MD | Specialist | Pittsburgh, PA | $78,261 | $0 |
| Swapnil Rajurkar, M.d, M.D | Medical Oncology | Upland, CA | $72,265 | $0 |
| Dr. Christopher Stokoe, Md, MD | Medical Oncology | Plano, TX | $70,821 | $0 |
| Edith Perez, Md, MD | Hematology & Oncology | Jacksonville, FL | $66,594 | $0 |
| Dr. Eleni Nackos, Md, MD | Hematology & Oncology | Westbrook, ME | $65,893 | $0 |
| Ricardo Alvarez, Md, MD | Medical Oncology | Houston, TX | $64,862 | $0 |
| Dr. Mabel Mardones, M.d, M.D | Internal Medicine | Denver, CO | $56,240 | $0 |
| Dr. Priya Rudolph, Md, Phd, MD, PHD | Hematology & Oncology | Athens, GA | $56,140 | $0 |
| Dr. Marina Vaysburd, M.d, M.D | Hematology & Oncology | Beverly Hills, CA | $52,519 | $0 |
| Virginia Kaklamani, Md, MD | Medical Oncology | San Antonio, TX | $50,935 | $0 |
| M. Donnelly, M.d, M.D | Medical Oncology | Gardner, MA | $47,397 | $0 |
| Dr. Jay Andersen, M.d, M.D | Hematology & Oncology | Portland, OR | $46,891 | $0 |
About Puma Biotechnology, Inc.
Puma Biotechnology, Inc. has made $38.7M in payments to 9,190 healthcare providers, recorded across 37,663 transactions in the CMS Open Payments database. In 2024, the company paid $3.5M. The top product by payment volume is NERLYNX ($19.9M).
Payments were distributed across 144 medical specialties. The top specialty by payment amount is Medical Oncology ($3.2M to 716 doctors).
Payment categories include: Food & Beverage ($801,763), Consulting ($3.6M), Research ($31.0M), Travel & Lodging ($610,940).
Puma Biotechnology, Inc. is associated with 2 products in the CMS Open Payments database.